Showing results (41-50 of 74) with videos related to

Sort By:
Pageof 8
Oncotarget|July 23, 2014
Thrombospondin 1 promotes an aggressive phenotype through epithelial-to-mesenchymal transition in human melanomaAparna Jayachandran, Matthew Anaka, Prashanth Prithviraj, et al.
International Journal of Molecular Sciences|October 23, 2021
Identification of Tumor Antigens in Ovarian Cancers Using Local and Circulating Tumor-Specific AntibodiesJessica Da Gama Duarte, Luke T Quigley, Anna Rachel Young, et al.
Clinical & Translational Immunology|December 31, 2019
Accumulation of CD103+ CD8+ T cells in a cutaneous melanoma micrometastasisKatharina Hochheiser, Han Xian Aw Yeang, Teagan Wagner, et al.
European Journal of Immunology|November 6, 2012
Flt3 ligand expands CD4+ FoxP3+ regulatory T cells in human subjectsOliver Klein, Lisa M Ebert, Damien Zanker, et al.
Cancer Immunology Research|April 6, 2016
Altered Expression and Splicing of ESRP1 in Malignant Melanoma Correlates with Epithelial-Mesenchymal Status and Tumor-Associated Immune Cytolytic ActivityJun Yao, Otavia L Caballero, Ying Huang, et al.
JAMA Oncology|July 31, 2020
Evaluation of Combination Nivolumab and Ipilimumab Immunotherapy in Patients With Advanced Biliary Tract Cancers: Subgroup Analysis of a Phase 2 Nonrandomized Clinical TrialOliver Klein, Damien Kee, Adnan Nagrial, et al.
Oncotarget|January 11, 2014
FOXP3 over-expression inhibits melanoma tumorigenesis via effects on proliferation and apoptosisBeeShin Tan, Matthew Anaka, Siddhartha Deb, et al.
Oncotarget|December 30, 2014
Whole exome sequencing identifies a recurrent RQCD1 P131L mutation in cutaneous melanomaStephen Q Wong, Andreas Behren, Victoria J Mar, et al.
Cell Death and Differentiation|October 1, 2016
Hepatocyte growth factor renders BRAF mutant human melanoma cell lines resistant to PLX4032 by downregulating the pro-apoptotic BH3-only proteins PUMA and BIMLeona Rohrbeck, Jia-Nan Gong, Erinna F Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 14, 2020
Immunotherapy of Ipilimumab and Nivolumab in Patients with Advanced Neuroendocrine Tumors: A Subgroup Analysis of the CA209-538 Clinical Trial for Rare CancersOliver Klein, Damien Kee, Ben Markman, et al.
Pageof 8